|
|
|
|
| LEADER |
01409nam a2200265 u 4500 |
| 001 |
EB001872424 |
| 003 |
EBX01000000000000001035795 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190824 r ||| eng |
| 245 |
0 |
0 |
|a Role of natriuretic peptides in diagnosing heart failure
|h Elektronische Ressource
|c Swedish Council on Technology Assessment in Health Care
|
| 260 |
|
|
|a Stockholm
|b Swedish Council on Technology Assessment in Health Care
|c 2006, 2006
|
| 300 |
|
|
|a 1 PDF file (3 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Heart Failure / diagnosis
|
| 653 |
|
|
|a Sweden
|
| 653 |
|
|
|a Atrial Natriuretic Factor
|
| 710 |
2 |
|
|a Statens beredning för utvärdering av medicinsk metodik (Sweden)
|
| 740 |
0 |
2 |
|a Natriuretiska peptider som hjälp vid diagnostik av hjärtsvikt
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a SBU alert report
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK448244
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 700
|
| 520 |
|
|
|a Conclusions Moderately strong scientific evidence shows that B-type natriuretic peptides (BNP or N-terminal proBNP) can be used, with good reliability, to rule out heart failure. However, evidence remains insufficient concerning the cost effectiveness of the method relative to other methods of diagnosing heart failure
|